Our patient, Richard Paduda, was featured today in a NY Times article on new strategies for hair growth and the prevention of hair loss.
Excerpt from the New York Times article by Douglas Quenqua, May 4 2011:
While the F.D.A. has not approved Latisse as a hair-loss treatment — only two drugs have that designation: minoxidil (Rogaine, also a topical medication) and finasteride (Propecia, which is administered in pill form) — there are no laws preventing doctors from prescribing it for that purpose. Dr. Bauman said he has been prescribing a generic form of bimatoprost, the active ingredient in Latisse, to combat hair loss since 2007, and that it has worked for about 70 percent of his patients.
“What we found is that where patients were applying Latisse, especially in areas where the hair was thinner and wispier and less pigmented, the hair grew thicker, stronger and healthier,” he said.
Though some users of Latisse have experienced skin discoloration, Dr. Bauman said he had never seen any such reaction on the scalp of his patients.
Certainly, Mr. Paduda, who used Latisse daily from November through February, is a happy customer. By the third week, he said, both he and friends he asked for reactions were seeing results. “I even busted out the old ‘before’ and ‘after’ pictures,” he said. “It was a noticeable difference.”
Regardless of what treatment you choose (topical minoxidil, bimatoprost, lasercap laser therapy, in-office laser hood treatments, NeoGraft FUE transplants, etc.) you should have baseline measurements and photos taken by a Diplomate of the American Board of Hair Restoration Surgery. Tracking should be performed every 90 days using HairCheck, scalp microscopy and standardized photos.
Boca Raton FL http://www.baumanmedical.com